Savara Presents New Data at ATS 2026 Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
- Clinical Trial Results: Savara showcased results from the IMPALA-2 Phase 3 clinical trial at the ATS 2026 conference, demonstrating that treatment with 300 µg of molgramostim significantly improves exercise capacity in patients with autoimmune pulmonary alveolar proteinosis (aPAP), indicating potential benefits for patient quality of life.
- Improved Exercise Capacity: At 48 weeks, patients in the molgramostim group walked an average of 167.0 meters further than the placebo group, which only increased by 86.4 meters, yielding a treatment difference of 80.6 meters (P=0.0301), highlighting the drug's significant impact on exercise performance.
- Extended Exercise Duration: Patients treated with molgramostim also experienced longer exercise durations, with an average increase of 2.0 minutes compared to 1.0 minute in the placebo group at 48 weeks, resulting in a treatment difference of 1.0 minute (P=0.0262), further supporting the clinical benefits of the treatment.
- Future Outlook: Dr. Yasmine Wasfi, Savara's Chief Medical Officer, noted that the consistent improvements across multiple exploratory endpoints strengthen the overall efficacy narrative, suggesting that molgramostim may translate into real-world functional benefits for aPAP patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SVRA
Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.090
Low
9.00
Averages
10.17
High
11.00
Current: 5.090
Low
9.00
Averages
10.17
High
11.00
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Savara Presents Long-Term Efficacy Data for Molgramostim at ATS Conference
- Clinical Trial Results: Savara presented long-term efficacy data from the IMPALA-2 clinical trial at the 2026 ATS International Conference, involving 164 patients, demonstrating significant effects of Molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP), reinforcing its potential as a treatment option.
- High Patient Retention: Following the double-blind period, 98% of patients opted to continue into the open-label (OL) phase, indicating the good tolerability of Molgramostim and strong patient endorsement of the treatment, which enhances the company's market confidence in this area.
- Sustained Efficacy Improvements: During the first 48 weeks of the OL period, patients receiving Molgramostim showed continuous improvements in pulmonary gas transfer (DLco%) and health-related quality of life (SGRQ-T and SGRQ-A scores), indicating the long-term efficacy and safety of the drug.
- Significant Crossover Effects: Patients who switched from placebo to Molgramostim during the OL period exhibited notable improvements in pulmonary gas transfer and quality of life scores, highlighting the drug's broad applicability and potential market opportunities across different patient populations.
See More
Savara Presents New Data at ATS 2026 Conference
- Clinical Trial Results: Savara showcased results from the IMPALA-2 Phase 3 clinical trial at the ATS 2026 conference, demonstrating that treatment with 300 µg of molgramostim significantly improves exercise capacity in patients with autoimmune pulmonary alveolar proteinosis (aPAP), indicating potential benefits for patient quality of life.
- Improved Exercise Capacity: At 48 weeks, patients in the molgramostim group walked an average of 167.0 meters further than the placebo group, which only increased by 86.4 meters, yielding a treatment difference of 80.6 meters (P=0.0301), highlighting the drug's significant impact on exercise performance.
- Extended Exercise Duration: Patients treated with molgramostim also experienced longer exercise durations, with an average increase of 2.0 minutes compared to 1.0 minute in the placebo group at 48 weeks, resulting in a treatment difference of 1.0 minute (P=0.0262), further supporting the clinical benefits of the treatment.
- Future Outlook: Dr. Yasmine Wasfi, Savara's Chief Medical Officer, noted that the consistent improvements across multiple exploratory endpoints strengthen the overall efficacy narrative, suggesting that molgramostim may translate into real-world functional benefits for aPAP patients.
See More
Savara Reports Q1 Earnings Miss with Negative EPS
- Earnings Report: Savara's Q1 GAAP EPS of -$0.15 missed expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence and stock performance.
- Financial Position: As of March 31, 2026, Savara reported approximately $202.8 million in cash and short-term investments against $30.1 million in debt, suggesting a solid cash reserve but a high debt level that could limit future investments and growth potential.
- FDA Review Update: The extension of the FDA review for Savara's lead asset introduces uncertainty regarding its product launch timeline, which could impact future revenue streams and market positioning.
- Market Sentiment: Seeking Alpha's Quant Rating reflects market concerns regarding Savara's financial performance, prompting investors to reassess the company's long-term prospects in the biopharmaceutical sector.
See More
Savara Inc. Grants Inducement Awards to New Employees
- Inducement Awards Granted: On April 14, 2026, Savara Inc. granted inducement awards to 24 new employees, comprising 18,500 stock options, 141,000 restricted stock units (RSUs), and 85,000 performance stock units (PSUs), aimed at attracting talent and enhancing employee loyalty.
- Stock Option Details: The granted options have an exercise price of $6.07 per share, matching the closing price on the grant date, with vesting occurring quarterly at a rate of 1/16th of the shares, ensuring continued employment for benefit acquisition.
- RSUs and PSUs Vesting: The RSUs will fully vest on the two-year anniversary of the employee's start date, while PSUs will vest upon the company reporting quarterly revenue exceeding a specified target, aligning employee incentives with company performance.
- Company Background: Savara focuses on clinical-stage biopharmaceuticals for rare respiratory diseases, with its lead product MOLBREEVI in Phase 3 development, demonstrating the company's commitment and capability to address unmet medical needs.
See More
Savara's FDA Review Period Extended for Molgramostim
- Review Period Extension: Savara announced that the FDA has extended the review period for its biologics license application (BLA) for molgramostim inhalation solution by three months, with a new target action date of November 22, up from the original August 22, indicating the FDA's attention to the application.
- Significant Amendment Impact: The FDA noted that Savara's responses to a recent information request represented a major amendment to the BLA, prompting the review period extension, which reflects the company's efforts to meet regulatory requirements.
- No Safety Issues: The FDA did not cite any issues related to the safety, efficacy, or manufacturing of molgramostim in its communications, providing Savara with a positive signal regarding the product's potential market outlook.
- Additional Review Time: This extension allows the FDA additional time to complete its review of the BLA, including recently submitted materials related to information requests, which may help expedite the final approval process.
See More
Savara's FDA Review for Molgramostim Delayed by Three Months
- FDA Review Delay: Savara's application for the experimental therapy molgramostim for Autoimmune Pulmonary Alveolar Proteinosis has seen its FDA review extended by three months, with the new decision deadline set for November 22, which may impact market expectations for the company.
- Major Amendment Submitted: The recent responses submitted by Savara to the FDA have been classified as a major amendment to the application, and while no safety, efficacy, or manufacturing concerns were cited, the additional review time could affect the approval timeline, potentially leading to decreased investor confidence.
- Market Opportunity: If approved, molgramostim could become the first and only therapy for Autoimmune PAP, following a previous refusal to file by the FDA in May 2025 due to insufficient data, indicating Savara's renewed confidence in the product with this resubmission.
- Muted Market Reaction: Despite SVRA stock doubling over the past 12 months, retail sentiment on Stocktwits remains neutral with low message volume, reflecting cautious investor reactions to the FDA review delay, which may affect short-term stock performance.
See More
Savara Presents Long-Term Efficacy Data for Molgramostim at ATS Conference
- Clinical Trial Results: Savara presented long-term efficacy data from the IMPALA-2 clinical trial at the 2026 ATS International Conference, involving 164 patients, demonstrating significant effects of Molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP), reinforcing its potential as a treatment option.
- High Patient Retention: Following the double-blind period, 98% of patients opted to continue into the open-label (OL) phase, indicating the good tolerability of Molgramostim and strong patient endorsement of the treatment, which enhances the company's market confidence in this area.
- Sustained Efficacy Improvements: During the first 48 weeks of the OL period, patients receiving Molgramostim showed continuous improvements in pulmonary gas transfer (DLco%) and health-related quality of life (SGRQ-T and SGRQ-A scores), indicating the long-term efficacy and safety of the drug.
- Significant Crossover Effects: Patients who switched from placebo to Molgramostim during the OL period exhibited notable improvements in pulmonary gas transfer and quality of life scores, highlighting the drug's broad applicability and potential market opportunities across different patient populations.
See More
Savara Presents New Data at ATS 2026 Conference
- Clinical Trial Results: Savara showcased results from the IMPALA-2 Phase 3 clinical trial at the ATS 2026 conference, demonstrating that treatment with 300 µg of molgramostim significantly improves exercise capacity in patients with autoimmune pulmonary alveolar proteinosis (aPAP), indicating potential benefits for patient quality of life.
- Improved Exercise Capacity: At 48 weeks, patients in the molgramostim group walked an average of 167.0 meters further than the placebo group, which only increased by 86.4 meters, yielding a treatment difference of 80.6 meters (P=0.0301), highlighting the drug's significant impact on exercise performance.
- Extended Exercise Duration: Patients treated with molgramostim also experienced longer exercise durations, with an average increase of 2.0 minutes compared to 1.0 minute in the placebo group at 48 weeks, resulting in a treatment difference of 1.0 minute (P=0.0262), further supporting the clinical benefits of the treatment.
- Future Outlook: Dr. Yasmine Wasfi, Savara's Chief Medical Officer, noted that the consistent improvements across multiple exploratory endpoints strengthen the overall efficacy narrative, suggesting that molgramostim may translate into real-world functional benefits for aPAP patients.
See More
Savara Reports Q1 Earnings Miss with Negative EPS
- Earnings Report: Savara's Q1 GAAP EPS of -$0.15 missed expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence and stock performance.
- Financial Position: As of March 31, 2026, Savara reported approximately $202.8 million in cash and short-term investments against $30.1 million in debt, suggesting a solid cash reserve but a high debt level that could limit future investments and growth potential.
- FDA Review Update: The extension of the FDA review for Savara's lead asset introduces uncertainty regarding its product launch timeline, which could impact future revenue streams and market positioning.
- Market Sentiment: Seeking Alpha's Quant Rating reflects market concerns regarding Savara's financial performance, prompting investors to reassess the company's long-term prospects in the biopharmaceutical sector.
See More
Savara Inc. Grants Inducement Awards to New Employees
- Inducement Awards Granted: On April 14, 2026, Savara Inc. granted inducement awards to 24 new employees, comprising 18,500 stock options, 141,000 restricted stock units (RSUs), and 85,000 performance stock units (PSUs), aimed at attracting talent and enhancing employee loyalty.
- Stock Option Details: The granted options have an exercise price of $6.07 per share, matching the closing price on the grant date, with vesting occurring quarterly at a rate of 1/16th of the shares, ensuring continued employment for benefit acquisition.
- RSUs and PSUs Vesting: The RSUs will fully vest on the two-year anniversary of the employee's start date, while PSUs will vest upon the company reporting quarterly revenue exceeding a specified target, aligning employee incentives with company performance.
- Company Background: Savara focuses on clinical-stage biopharmaceuticals for rare respiratory diseases, with its lead product MOLBREEVI in Phase 3 development, demonstrating the company's commitment and capability to address unmet medical needs.
See More
Savara's FDA Review Period Extended for Molgramostim
- Review Period Extension: Savara announced that the FDA has extended the review period for its biologics license application (BLA) for molgramostim inhalation solution by three months, with a new target action date of November 22, up from the original August 22, indicating the FDA's attention to the application.
- Significant Amendment Impact: The FDA noted that Savara's responses to a recent information request represented a major amendment to the BLA, prompting the review period extension, which reflects the company's efforts to meet regulatory requirements.
- No Safety Issues: The FDA did not cite any issues related to the safety, efficacy, or manufacturing of molgramostim in its communications, providing Savara with a positive signal regarding the product's potential market outlook.
- Additional Review Time: This extension allows the FDA additional time to complete its review of the BLA, including recently submitted materials related to information requests, which may help expedite the final approval process.
See More
Savara's FDA Review for Molgramostim Delayed by Three Months
- FDA Review Delay: Savara's application for the experimental therapy molgramostim for Autoimmune Pulmonary Alveolar Proteinosis has seen its FDA review extended by three months, with the new decision deadline set for November 22, which may impact market expectations for the company.
- Major Amendment Submitted: The recent responses submitted by Savara to the FDA have been classified as a major amendment to the application, and while no safety, efficacy, or manufacturing concerns were cited, the additional review time could affect the approval timeline, potentially leading to decreased investor confidence.
- Market Opportunity: If approved, molgramostim could become the first and only therapy for Autoimmune PAP, following a previous refusal to file by the FDA in May 2025 due to insufficient data, indicating Savara's renewed confidence in the product with this resubmission.
- Muted Market Reaction: Despite SVRA stock doubling over the past 12 months, retail sentiment on Stocktwits remains neutral with low message volume, reflecting cautious investor reactions to the FDA review delay, which may affect short-term stock performance.
See More
